Synovial Fibroblast 3.1: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 1 of 2) - Dataset (ID:20234)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA2708 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 4 | MIP-1A | 1029.0 | 25 | |
RA2708 | Poly(I:C) | 2 | ug/mL | 4 | MIP-1A | 997.0 | 20 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | MIP-1A | 23.5 | 32 | |
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | MIP-1A | 33.5 | 38 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | MIP-1A | 19.0 | 38 | |
N2645 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | MIP-1A | 23.0 | 32 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | MIP-1A | 21.0 | 25 | |
RA2708 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | MIP-1A | 37.5 | 24 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | MIP-1A | 246.0 | 38 | |
RA2159 | IL-1 alpha | 100 | ng/mL | 4 | MIP-1A | 108.5 | 22 | ||||
N2645 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | MIP-1A | 50.0 | 26 | |
N2645 | IL-1 alpha | 100 | ng/mL | 4 | MIP-1A | 47.5 | 24 | ||||
RA2708 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | MIP-1A | 148.0 | 33 | |
RA2708 | IL-1 alpha | 100 | ng/mL | 4 | MIP-1A | 103.0 | 25 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | MIP-1A | 60.0 | 31 | |
RA2159 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | MIP-1A | 60.0 | 39 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | MIP-1A | 35.0 | 31 | |
N2645 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | MIP-1A | 42.0 | 41 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | MIP-1A | 64.0 | 27 | |
RA2708 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | MIP-1A | 56.0 | 36 | |
RA2159 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | MIP-1A | 63.0 | 49 | |
RA2159 | TNF-a | 100 | ng/mL | 4 | MIP-1A | 87.0 | 29 | ||||
N2645 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | MIP-1A | 57.5 | 30 | |
N2645 | TNF-a | 100 | ng/mL | 4 | MIP-1A | 69.0 | 25 | ||||
RA2708 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | MIP-1A | 60.0 | 25 |